Abstract：
This study aims to estimate the population-based incidence of gestational trophoblastic diseases (GTDs) and to identify the characteristics of gestational trophoblastic neoplasia (GTN) in Japan.
The annual number of GTD and live births from 1974 to 2018 were used to estimate the incidence of GTD. The data of 1,574 GTN cases from 1999 to 2018 were analyzed to identify the characteristics of low-risk GTN, high-risk GTN, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT).
The incidence of hydatidiform mole was 2.02 per 1,000 live births on average which decreased from 1974 to 2008 and increased from 2009 to 2018. The incidence of low-risk GTN, high-risk GTN, PSTT, and ETT was 15.3, 3.5, 0.3, and 0.07 per 100,000 live births, respectively. The estimated incidence of post-molar GTN was 9.8% of molar patients. High-risk GTN was diagnosed more pathologically, had more various kinds of antecedent pregnancies, and had longer intervals after the antecedent pregnancy compared to low-risk GTN. Furthermore, 8.2% of high-risk GTN occurred after the subsequent non-molar pregnancy of hydatidiform mole. The cumulative percentage of developing high-risk GTN after hydatidiform mole reached 89.3% at the 60th month.
The incidence of hydatidiform mole, low-risk GTN, high-risk GTN was 2.02 per 1,000 live births, 15.3 per 100,000 live births, and 3.5 per 100,000 live births, respectively. High-risk GTN was diagnosed more pathologically and later after the antecedent pregnancy than low-risk GTN. Following molar patients for five years is needed to improve the mortality of malignant GTN.
The annual number of GTD and live births from 1974 to 2018 were used to estimate the incidence of GTD. The data of 1,574 GTN cases from 1999 to 2018 were analyzed to identify the characteristics of low-risk GTN, high-risk GTN, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT).
The incidence of hydatidiform mole was 2.02 per 1,000 live births on average which decreased from 1974 to 2008 and increased from 2009 to 2018. The incidence of low-risk GTN, high-risk GTN, PSTT, and ETT was 15.3, 3.5, 0.3, and 0.07 per 100,000 live births, respectively. The estimated incidence of post-molar GTN was 9.8% of molar patients. High-risk GTN was diagnosed more pathologically, had more various kinds of antecedent pregnancies, and had longer intervals after the antecedent pregnancy compared to low-risk GTN. Furthermore, 8.2% of high-risk GTN occurred after the subsequent non-molar pregnancy of hydatidiform mole. The cumulative percentage of developing high-risk GTN after hydatidiform mole reached 89.3% at the 60th month.
The incidence of hydatidiform mole, low-risk GTN, high-risk GTN was 2.02 per 1,000 live births, 15.3 per 100,000 live births, and 3.5 per 100,000 live births, respectively. High-risk GTN was diagnosed more pathologically and later after the antecedent pregnancy than low-risk GTN. Following molar patients for five years is needed to improve the mortality of malignant GTN.
摘要：
这项研究旨在估计日本以人群为基础的妊娠滋养细胞疾病（GTD）的发病率，并确定妊娠滋养细胞肿瘤（GTN）的特征。
使用1974年至2018年的GTD和活产的年度数量来估计GTD的发生率。对1999年至2018年的1574例GTN病例进行分析，以确定低风险GTN的特征，高风险的GTN,胎盘部位滋养细胞肿瘤（PSTT），和上皮样滋养细胞肿瘤（ETT）。
葡萄胎的发病率平均为每千名活产2.02，从1974年到2008年下降，从2009年到2018年上升。低风险GTN的发生率，高风险的GTN,PSTT,ETT为每100,000活产15.3、3.5、0.3和0.07，分别。磨牙后GTN的估计发生率为磨牙患者的9.8％。高风险的GTN被诊断为更多的病理，有更多种类的先前怀孕，与低风险GTN相比，前期妊娠后的间隔时间更长。此外，8.2%的高危GTN发生在葡萄胎的非磨牙妊娠后。葡萄胎后发生高危GTN的累积百分比在第60个月达到89.3％。
葡萄胎的发生率，低风险GTN，高风险GTN为2.02/1000活产，每100,000名活产15.3名，每100,000名活产中有3.5名，分别。与低风险GTN相比，高风险GTN在病理上被诊断为更多，并且在前期妊娠后更晚。磨牙患者需要随访五年才能改善恶性GTN的死亡率。
使用1974年至2018年的GTD和活产的年度数量来估计GTD的发生率。对1999年至2018年的1574例GTN病例进行分析，以确定低风险GTN的特征，高风险的GTN,胎盘部位滋养细胞肿瘤（PSTT），和上皮样滋养细胞肿瘤（ETT）。
葡萄胎的发病率平均为每千名活产2.02，从1974年到2008年下降，从2009年到2018年上升。低风险GTN的发生率，高风险的GTN,PSTT,ETT为每100,000活产15.3、3.5、0.3和0.07，分别。磨牙后GTN的估计发生率为磨牙患者的9.8％。高风险的GTN被诊断为更多的病理，有更多种类的先前怀孕，与低风险GTN相比，前期妊娠后的间隔时间更长。此外，8.2%的高危GTN发生在葡萄胎的非磨牙妊娠后。葡萄胎后发生高危GTN的累积百分比在第60个月达到89.3％。
葡萄胎的发生率，低风险GTN，高风险GTN为2.02/1000活产，每100,000名活产15.3名，每100,000名活产中有3.5名，分别。与低风险GTN相比，高风险GTN在病理上被诊断为更多，并且在前期妊娠后更晚。磨牙患者需要随访五年才能改善恶性GTN的死亡率。
